Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
21.56
+1.03 (5.02%)
Jul 31, 2026, 3:00 PM CST

SHA:688319 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
56.5222.2620.7617.5626.58107.96
Depreciation & Amortization
37.7237.7232.4730.8125.323.04
Other Amortization
5.345.343.533.153.431.64
Loss (Gain) From Sale of Assets
-0.01-0.010.030.150.150.01
Loss (Gain) From Sale of Investments
-0.5-0.5-0.86-1.04-3.7-3.76
Provision & Write-off of Bad Debts
13.2113.2110.191.7212.189
Other Operating Activities
-8.1528.046.675.669.130.12
Change in Accounts Receivable
-84.65-84.65-83.630.98-151.92-147.16
Change in Inventory
9.719.71-13.571.68-7.96-27.28
Change in Accounts Payable
75.1375.1319.06-12.364.4681.2
Operating Cash Flow
103.57105.49-9.7344-24.5539.96
Operating Cash Flow Growth
222.06%----89.49%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-103.33-98.81-207.32-169.88-200.69-69.71
Sale of Property, Plant & Equipment
0.030.030.03--0.01
Investment in Securities
-19.11-24.21-17.590140-190
Other Investing Activities
0.550.50.861.043.73.76
Investing Cash Flow
-121.86-122.49-223.93-78.84-56.99-255.94

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-176.1206.82208.25129.9935
Total Debt Issued
151.1176.1206.82208.25129.9935
Long-Term Debt Repaid
--119.65-78.85-100.06-40-27.34
Total Debt Repaid
-108.08-119.65-78.85-100.06-40-27.34
Net Debt Issued (Repaid)
43.0256.45127.97108.1989.997.66
Issuance of Common Stock
---10.3817.65371.81
Repurchase of Common Stock
-2.38-2.38-2.39---
Common Dividends Paid
-15.18-14.72-29.68-5.99-4.25-1.03
Other Financing Activities
-21.4-14.95-16.68--9.64
Financing Cash Flow
4.0624.495.91129.27103.38368.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-14.237.4-137.7694.4221.84152.82

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
0.246.68-217.05-125.88-225.24-29.75
Free Cash Flow Growth
------
Free Cash Flow Margin
0.03%0.95%-36.86%-25.37%-41.14%-6.11%
Free Cash Flow Per Share
0.000.02-0.54-0.31-0.56-0.08
Levered Free Cash Flow
-31.1413.44-200.57-140.57-198.44-67.11
Unlevered Free Cash Flow
-21.5222.81-191.53-136.09-195.27-66.34

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
65.6552.1425.5934.193516.56
Change in Working Capital
-0.57-0.57-82.52-14-97.61-98.05